Drug Profile
RO 256981
Alternative Names: RO 25-6981Latest Information Update: 04 Dec 2008
Price :
$50
*
At a glance
- Originator Roche
- Class Antiparkinsonians; Neuroprotectants; Small molecules
- Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 15 Feb 2006 No development reported - Preclinical for Neurological disorders (Prevention) in Switzerland (unspecified route)
- 01 Sep 2003 This compound is still in active development
- 26 Jun 2001 No-Development-Reported for Neurological disorders (Prevention) in Switzerland (Unknown route)